DK0485430T3 - Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis - Google Patents

Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis

Info

Publication number
DK0485430T3
DK0485430T3 DK90911485T DK90911485T DK0485430T3 DK 0485430 T3 DK0485430 T3 DK 0485430T3 DK 90911485 T DK90911485 T DK 90911485T DK 90911485 T DK90911485 T DK 90911485T DK 0485430 T3 DK0485430 T3 DK 0485430T3
Authority
DK
Denmark
Prior art keywords
sepsis
compositions
methods
improving symptoms
antibody molecules
Prior art date
Application number
DK90911485T
Other languages
Danish (da)
English (en)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John C Mathison
Original Assignee
Scripps Research Inst
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Rockefeller filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0485430T3 publication Critical patent/DK0485430T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
DK90911485T 1989-08-01 1990-07-30 Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis DK0485430T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01
PCT/US1990/004250 WO1991001639A1 (en) 1989-08-01 1990-07-30 Methods and compositions for ameliorating the symptoms of sepsis

Publications (1)

Publication Number Publication Date
DK0485430T3 true DK0485430T3 (da) 1999-06-14

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911485T DK0485430T3 (da) 1989-08-01 1990-07-30 Fremgangsmåder og sammensætninger til bedring af symptomer på sepsis

Country Status (14)

Country Link
US (4) US5730980A (de)
EP (1) EP0485430B1 (de)
JP (1) JP2744130B2 (de)
AT (1) ATE171042T1 (de)
AU (1) AU645515B2 (de)
CA (1) CA2022429C (de)
DE (1) DE69032662T2 (de)
DK (1) DK0485430T3 (de)
ES (1) ES2120948T3 (de)
FI (1) FI920450A0 (de)
GR (1) GR1003164B (de)
IE (1) IE902770A1 (de)
PT (1) PT94869B (de)
WO (1) WO1991001639A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171042T1 (de) * 1989-08-01 1998-10-15 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US5731415A (en) 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
ES2255708T3 (es) 1994-09-16 2006-07-01 The Scripps Research Institute Uso de anticuerpos para bloquear los efectos de las bacterias gram-positivas y las micobacterias.
JPH10512142A (ja) * 1994-12-30 1998-11-24 アムジエン・インコーポレーテツド 抗炎症性ｃｄ１４ポリペプチド
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
AU5688596A (en) * 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
AU735058B2 (en) 1996-05-10 2001-06-28 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
PL194240B1 (pl) * 1998-02-07 2007-05-31 British Biotech Pharm Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy
BR9910725A (pt) * 1998-05-27 2001-01-30 Gemma Biotechnology Ltd Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
US6916628B1 (en) 1999-09-17 2005-07-12 Mochida Pharmaceutical Co., Ltd. Method for the measurement of soluble CD14 proteins separately
EP1336620A4 (de) * 2000-11-22 2004-11-17 Mochida Pharm Co Ltd Monoklonaler, die cd14/tlr-bindung hemmender anti-cd14-antikörper
AU2002221099A1 (en) * 2000-12-08 2002-06-18 Takeda Chemical Industries Ltd. Combination drugs
AU2003253621A1 (en) * 2002-06-14 2003-12-31 Centocor, Inc. Modified "s" antibodies
EP2266606B1 (de) * 2003-05-15 2014-09-10 Genentech, Inc. Verfahren und Zubereitungen zur Prävention und Behandlung von Blutvergiftung
WO2006093794A1 (en) * 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN103665168A (zh) 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
AU2018255489B2 (en) 2017-04-21 2024-06-13 Implicit Bioscience Limited CD 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
ATE171042T1 (de) * 1989-08-01 1998-10-15 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis

Also Published As

Publication number Publication date
EP0485430A1 (de) 1992-05-20
AU645515B2 (en) 1994-01-20
FI920450A7 (fi) 1992-01-31
CA2022429A1 (en) 1991-02-02
DE69032662D1 (de) 1998-10-22
PT94869B (pt) 1997-04-30
US5730980A (en) 1998-03-24
US6297049B1 (en) 2001-10-02
EP0485430A4 (en) 1993-03-03
US6045795A (en) 2000-04-04
WO1991001639A1 (en) 1991-02-21
ES2120948T3 (es) 1998-11-16
US6495332B2 (en) 2002-12-17
EP0485430B1 (de) 1998-09-16
PT94869A (pt) 1991-04-18
GR1003164B (el) 1999-07-05
ATE171042T1 (de) 1998-10-15
FI920450A0 (fi) 1992-01-31
AU6146190A (en) 1991-03-11
GR900100582A (el) 1991-12-30
JP2744130B2 (ja) 1998-04-28
US20020034509A1 (en) 2002-03-21
CA2022429C (en) 1998-12-01
JPH05501399A (ja) 1993-03-18
IE902770A1 (en) 1991-02-27
DE69032662T2 (de) 1999-03-11

Similar Documents

Publication Publication Date Title
ATE171042T1 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
EP0938505A4 (de) Monoklonale antikörper gegen endoglin und ihre verwendung in der antiangiogenen therapie
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
DE69132048D1 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
FI884375A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(1-alkyyli-3-hydroksi-4-piperidinyyli)bentsamidien valmistamiseksi
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ATE239709T1 (de) Racemisches huperzin a
DK0506658T3 (da) Sammensætninger og fremgangsmåde til behandling af smertefulde, inflammatoriske eller allergiske lidelser
DK0792162T3 (da) Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
FI883378A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(3-hydroksi-4-piperidinyyli)bentsamidien valmistamiseksi
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
DK0643585T3 (da) Anvendelsen af lipoprotein-associeret koagulationsinhibitor (LACI) til fremstilling af et lægemiddel til behandlingen af ak
RU2003100517A (ru) Новый интерферон для лечения рассеянного склероза
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
NO955263L (no) N-substituerte azaheterosykliske karboksylsyrer og estere derav
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ES535091A0 (es) Procedimiento de obtencion de una fraccion de hidrocarburos a partir de cera de abeja.
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
DK0487660T3 (da) Behandling af trombosetilfælde
MA23755A1 (fr) Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires
NO952608L (no) Derivatiserte kalsitoniner